The prognostic value of chemotherapy or endocrine therapy choice according to circulating tumor cell count in HR(+)HER2(−) metastatic breast cancer: a retrospective study

BACKGROUND: Circulating tumor cell (CTC) count have prognostic role for metastatic breast cancer (MBC). No clear biomarkers can guide selection of chemotherapy (CT) or endocrine therapy (ET) in 1st-line setting of hormone-receptor positive and human epidermal growth factor receptor 2 negative (HR(+)...

Descripción completa

Detalles Bibliográficos
Autores principales: Shao, Bin, Li, Huiping, Zhang, Jiayang, Liu, Xiaoran, Song, Guohong, Jiang, Hanfang, Yan, Ying, Wang, Huan, Wang, Jing, Di, Lijun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9469166/
https://www.ncbi.nlm.nih.gov/pubmed/36111005
http://dx.doi.org/10.21037/atm-22-3797

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9469166/
https://www.ncbi.nlm.nih.gov/pubmed/36111005
http://dx.doi.org/10.21037/atm-22-3797

Ejemplares similares